Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
In a deal worth up to $562.5 million, Biogen Idec is acquiring privately held Stromedix. Biogen gains STX-100, a monoclonal antibody poised to enter Phase II trials as an idiopathic pulmonary fibrosis treatment. Stromedix investors will receive $75 million up front and up to $487.5 million more contingent on reaching certain milestones for STX-100. Stromedix was founded in 2005 by Biogen’s former head of research, Michael Gilman. The firm subsequently licensed STX-100 from Biogen, completed Phase I trials, and developed biomarkers to facilitate patient selection for future studies.
This article has been sent to the following recipient: